“Increased Uptake of Biosimilars and Generics in Oncology Supportive Care”
- A notable and growing trend in the Asia-Pacific cancer supportive care products market is the widening acceptance and adoption of biosimilars and generics, especially in resource-constrained healthcare settings. These cost-effective alternatives are improving access to essential supportive care therapies such as granulocyte colony stimulating factors (GCSFs), erythropoietin stimulating agents (ESAs), and anti-emetics.
- For instance, India and China have seen increased production and regulatory approvals for biosimilars, enabling wider distribution in both domestic and export markets. Companies like Dr. Reddy’s Laboratories and Biocon are leading players offering oncology biosimilars that match global standards in efficacy and safety.
- The use of biosimilars not only reduces treatment costs but also alleviates pressure on healthcare systems by ensuring consistent availability of supportive therapies. This trend is especially prominent in public hospital settings, where affordability and accessibility are critical concerns.
- Furthermore, government efforts to streamline regulatory pathways, such as Japan’s PMDA and South Korea’s MFDS, have accelerated biosimilar market penetration across the region.
- This increased availability and physician trust in biosimilars is shifting the competitive landscape, encouraging multinational pharma companies to expand local partnerships or manufacture region-specific versions to remain competitive.
- As the burden of cancer rises and demand for cost-effective care intensifies, biosimilars are expected to play a central role in shaping the market's future trajectory, especially across low- and middle-income countries in the region.
